David Johnson, Chief Executive Officer

David Johnson was President of the ConvaTec division of Bristol-Myers Squibb until 2008 when he orchestrated a sale of the division from its pharmaceutical parent to Avista Capital Partners and Nordic Capital in a deal valued at $4.1 billion. Concurrently, he acquired and integrated the assets of Copenhagen-based Unomedical to expand ConvaTec Inc.’s manufacturing and infrastructure into Europe.From 2008 through 2012, Mr. Johnson served as the Chief Executive Officer of ConvaTec Inc. Prior to his tenure with ConvaTec Inc., Mr. Johnson held several senior positions in the U.S., Europe and Canada with Zimmer Inc., Fisher Scientific, and Baxter Corporation. He served as a member of ConvaTec Inc.’s Board of Directors and the Board of the Advanced Medical Technology Association (AdvaMed), where he chaired the Global Wound Sector Team for four years. Mr. Johnson received an undergraduate business degree in marketing from the Northern Alberta Institute of Technology in Edmonton, Alberta, Canada, completed the INSEAD Advanced Management Program in Fontainbleau, France, and is a fellow from the Wharton School of the University of Pennsylvania.

Brian M. Posner, Chief Financial Officer

Brian Posner is a strategic and financial leader with more than 25 years of diversified management experience, working in both public and private companies ranging from startup to $1B in revenue. Most recently he served as CFO of Ocean Power Technologies, Inc., a pioneer in wave-energy technology. Prior to that appointment, he served as CFO of Power Medical Interventions, Inc. until its sale to Covidien plc in 2009. He earlier served as CFO of Pharmacopeia, Inc. and Phytomedics, Inc., and as Regional CFO of Omnicare, Inc. Mr. Posner is a Certified Public Accountant and earned an MBA in Managerial Accounting from Pace University\’s Lubin School of Business and a BA in Accounting from Queens College.

Brad C. Barton, Chief Operating Officer

Brad Barton was formerly the President of ConvaTec Americas with responsibility for all ConvaTec businesses in the U.S., Canada, and Latin America. During his time at ConvaTec, Mr. Barton led the team responsible for the acquisition and integration of 180 Medical and Abviser. Mr. Barton was instrumental in helping to establish Convatec as a standalone company in the Americas and also helped transition the Company after its sale to Nordic Capital and Avista Capital Partners.Prior to his America’s role, Mr. Barton had responsibilities for ConvaTec’s business in China, Asia, Japan, and Australia. Other senior roles at ConvaTec helped Mr. Barton hone his extensive knowledge of U.S. distribution channels, GPO’s, and the post acute care market segment. Mr. Barton has held a number of sales leadership roles at Calgon Corp. and Vestal Laboratories.

Nino Pionati, Chief Strategy and Marketing Officer

Nino Pionati joins Alliqua from Bayer HealthCare Pharmaceuticals, where he was the Vice President of Marketing for Bayer’s Essure portfolio and a member of the Global Franchise and Women’s Health Care Leadership teams. Prior to joining Bayer, Mr. Pionati spent over 14 years at ConvaTec and Bristol Myers Squibb, where he held several global marketing positions at the corporate level, including President of Global Marketing, Business Development and International and President of the Intercontinental Region. Mr. Pionati also progressed through positions of increasing responsibility during his 13 years at Johnson & Johnson, and co-led the strategic development of internally-backed startup, J & J Independence Technologies, including sales, service, clinical, regulatory and marketing. Mr. Pionati holds an MBA from the University of Pittsburg’s Katz School of Business and a Bachelors of Commerce in Marketing from Concordia University of Montreal.

Dr. Janice M. Smiell, M.D., Chief Medical Officer

Dr. Janice Smiell, M.D. brings over twenty years of wound care, regenerative medicine, and clinical development experience to Alliqua. She is the former VP of Medical Affairs at LifeCell Corporation, where she oversaw clinical development and product safety programs from 2007 to 2011. LifeCell develops and markets tissue repair products for use in reconstructive, urogynecologic, and orthopedic surgical procedures. Prior to joining LifeCell, Dr. Smiell was the Executive Director of Global Clinical R&D at Celgene, where she led the clinical development of biomaterials and stem cells at the Company’s Cellular Therapeutics Division.From 1994 to 2003, Dr. Smiell was the Senior Director of Global Clinical R&D at Johnson and Johnson where she was awarded the prestigious Johnson Medal in recognition of her development work on Regranex, a growth factor for wound healing. Before joining Johnson and Johnson, Dr. Smiell served as the Medical Director of the Wound Care Center at Morristown Memorial Hospital. Dr. Smiell received her M.D. from the Medical College of Pennsylvania in Philadelphia (now Drexel University School of Medicine).

Gregory Robb, VP Operations

Gregory Robb has over 20 years of experience working with and manufacturing electron beam cross-linked hydrogels. Mr. Robb coordinated and supervised the construction of the AquaMed facility and has overseen product development, production, process improvements, while also serving as the primary point of customer contact. Prior to joining AquaMed, Mr. Robb was the Project Engineer and Facility Manager at E-Beam Services, where he was responsible for the expansion of the business, including the installation of a 10 MeV linear accelerator. Mr. Robb holds a Bachelor of Science degree in Mechanical Engineering from Trenton State College.